Market Spotlight: Eating Disorders
Market Spotlight: Eating Disorders
$1,318.00
This Market Spotlight report covers the Eating Disorders market, comprising key marketed and pipeline drugs, clinical trials, upcoming events, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Author: Informa Pharma Intelligence
Publisher: Datamonitor Healthcare
- Description
- Contents
This Market Spotlight report covers the Eating Disorders market, comprising key marketed and pipeline drugs, clinical trials, upcoming events, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Key Takeaways
- Worldwide, Datamonitor Healthcare estimates that in 2017, there were approximately 35.6 million prevalent cases of eating disorders in females aged 10–19 years, including 3.0 million cases of anorexia nervosa, 11.6 million cases of bulimia nervosa, and 14.3 million cases of binge eating disorder.
- In this demographic group, Datamonitor Healthcare forecasts the number of prevalent cases of eating disorders to increase to 38.1 million by 2026.
- Edgemont’s fluoxetine tablets, Eli Lilly’s Prozac, and Takeda’s Vyvanse are the only FDA-approved drugs for eating disorders. These drugs are administered via the oral route, with Vyvanse also available in an intranasal formulation.
- The only industry-sponsored drug in active clinical development for eating disorders is in Phase II. Relamorelin, which targets ghrelin receptor, is the only therapy in active clinical development for eating disorders. It is being tested as a subcutaneous formulation.
- The overall likelihood of approval of a Phase I eating disorders asset is 8.9%, and the average probability a drug advances from Phase III is 66.7%. Drugs, on average, take 5.8 years from Phase I to approval, compared to 8.9 years in the overall psychiatry space.
- All of the clinical trials for eating disorders have been in Phase III. The US leads in terms of the number of eating disorders clinical trials globally, while Germany leads the major European markets.
- Clinical trial activity in the eating disorders space consists entirely of completed trials. Takeda has the highest number of completed clinical trials for eating disorders, with three trials.
- Takeda leads industry sponsors with the highest number of Phase III clinical trials for eating disorders, followed by Johnson & Johnson.
CONTENTS
5 OVERVIEW
6 KEY TAKEAWAYS
7 DISEASE BACKGROUND
7 Subtypes
8 TREATMENT
8 Psychotherapy
8 Medications
9 EPIDEMIOLOGY
18 MARKETED DRUGS
20 PIPELINE DRUGS
24 RECENT EVENTS AND ANALYST OPINION
24 Relamorelin for Eating Disorders (June 25, 2019)
25 OPNT001 for Eating Disorders (February 21, 2019)
27 PROBABILITY OF SUCCESS
28 REVENUE OPPORTUNITY
29 CLINICAL TRIAL LANDSCAPE
30 Sponsors by status
31 Sponsors by phase
33 BIBLIOGRAPHY
33 Prescription information
35 APPENDIX
LIST OF FIGURES
11 Figure 1: Trends in worldwide prevalent cases of eating disorders in females aged 10–19 years, 2017–26
20 Figure 2: Overview of pipeline drugs for eating disorders in the US
20 Figure 3: Pipeline drugs for eating disorders, by company
20 Figure 4: Pipeline drugs for eating disorders, by drug type
21 Figure 5: Pipeline drugs for eating disorders, by classification
26 Figure 6: OPNT001 for Eating Disorders (February 21, 2019): Phase II – Bulimia Nervosa (U.K.)
27 Figure 7: Probability of success in the eating disorders pipeline
29 Figure 8: Clinical trials in eating disorders
29 Figure 9: Top 10 drugs for clinical trials in eating disorders
30 Figure 10: Top 10 companies for clinical trials in eating disorders
30 Figure 11: Trial locations in eating disorders
31 Figure 12: Eating disorders trials status
32 Figure 13: Eating disorders trials sponsors, by phase
LIST OF TABLES|
10 Table 1: Worldwide prevalent cases of eating disorders in females aged 10–19 years, 2017–26
2 Table 2: Prevalent cases of eating disorders in females aged 10–19 years in Africa, 2017–26
13 Table 3: Prevalent cases of eating disorders in females aged 10–19 years in Asia, 2017–26
14 Table 4: Prevalent cases of eating disorders in children aged 10–19 years in Latin America and the Caribbean, 2017–26
15 Table 5: Prevalent cases of eating disorders in children aged 10–19 years in Northern America, 2017–26
16 Table 6: Prevalent cases of eating disorders in children aged 10–19 years in Oceania, 2017–26
17 Table 7: Prevalent cases of eating disorders in all ages in Europe, 2017–26
19 Table 8: Marketed drugs for eating disorders
22 Table 9: Pipeline drugs for eating disorders in the US
24 Table 10: Relamorelin for Eating Disorders (June 25, 2019)
25 Table 11: OPNT001 for Eating Disorders (February 21, 2019)
28 Table 12: Historical global sales, by drug ($m), 2015-19
28 Table 13: Forecasted global sales, by drug ($m), 2020–24
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Market Spotlight: Norovirus 
Sign up to the